Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTao YouHHHaiwen Huang

Discussion

Loading...

Member takes

Overview

Analysis reveals promising efficacy and manageable toxicity of modified BEAC in DLBCL patients, suggesting improved outcomes.

Key Points

  • Assess the safety and efficacy of CAR-T therapy after modified BEAC lymphodepletion in r/r DLBCL patients.
  • Retrospective analysis of 12 DLBCL patients undergoing CAR-T post-autologous stem cell support.
  • Utilized modified BEAC regimen for lymphodepletion with specific drug doses.
  • Evaluated treatment outcomes including overall response rates and survival using Kaplan-Meier curves.
  • Overall response rate was 91.7%, with a complete remission rate of 83.3%.
  • All patients experienced grade 4 cytopenias post-treatment, while delayed grade ≥3 cytopenias were infrequent.
  • Overall survival rate was 100% after a median follow-up of 9.3 months.

Cite This Study

You et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df50https://doi.org/10.1182/blood-2025-3719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  2. 2Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2026
  3. 3CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  4. 4Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study2025
  5. 5Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025